A Label-Free Cell Sorting Approach to Highlight the Impact of Intratumoral Cellular Heterogeneity and Cancer Stem Cells on Response to Therapies

Cells. 2022 Jul 22;11(15):2264. doi: 10.3390/cells11152264.

Abstract

Cancer stem cells play a crucial role in tumor initiation, metastasis, and resistance to treatment. Cellular heterogeneity and plasticity complicate the isolation of cancer stem cells. The impact of intra-tumor cellular heterogeneity using a label-free approach remains understudied in the context of treatment resistance. Here, we use the sedimentation field-flow fractionation technique to separate, without labeling, cell subpopulations of colorectal cancer cell lines and primary cultures according to their biophysical properties. One of the three sorted cell subpopulations exhibits characteristics of cancer stem cells, including high tumorigenicity in vivo and a higher frequency of tumor-initiating cells compared to the other subpopulations. Due to its chemoresistance, two- and three-dimensional in vitro chemosensitivity assays highlight the therapeutic relevance of this cancer stem cell subpopulation. Thus, our results reveal the major implication of intra-tumor cellular heterogeneity, including cancer stem cells in treatment resistance, thanks to our label-free cell sorting approach. This approach enables-by breaking down the tumor-the study the individualized response of each sorted tumor cell subpopulation and to identify chemoresistance, thus offering new perspectives for personalized therapy.

Keywords: cancer stem cells; chemoresistance; colorectal cancer; intratumoral cellular heterogeneity; label-free cell sorting.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Cell Movement
  • Cell Separation
  • Cell Transformation, Neoplastic* / metabolism
  • Humans
  • Neoplastic Stem Cells* / pathology

Grants and funding

This research was funded by the ‘Comité Départemental de La Haute-Vienne de la Ligue Nationale Contre le Cancer’, by the ‘Comité d’Orientation de la Recherche en Cancérologie’ (CORC) of Limoges and received a donation from the family of Mr Ballihi.